Sex: F
Vaccine: COVID19, UNK
Symptoms: Condition aggravated
Clinical narrative: Autoimmune flared/Joints hurt; This spontaneous case was reported by a consumer and describes the occurrence of CONDITION AGGRAVATED (Autoimmune flared/Joints hurt) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    Concurrent medical conditions included COPD and Rheumatoid arthritis.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. On an unknown date, the patient experienced CONDITION AGGRAVATED (Autoimmune flared/Joints hurt) (seriousness criterion medically significant). At the time of the report, CONDITION AGGRAVATED (Autoimmune flared/Joints hurt) had resolved.            Concomitant medication was not provided. Treatment medication information was not provided by the reporter. It was repored that on unknown dates, rinvoq not helping like it did in the beginning, joints hurt copd/lung issues that have gotten worse since starting rinvoq. In Oct 2021 she stopped Rinvoq at physicians. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  CC: This spontaneous case concerns an adult, female patient with concurrent conditions of rheumatoid arthritis and chronic obstructive pulmonary disease, who experienced an unexpected, medically significant event of Condition aggravated after receiving a 3rd dose of mRNA-1273 vaccine. Exact latency of the event autoimmune flared relative to vaccination cannot be determined with unknown event's onset date and vaccine administration date. Reportedly, the event autoimmune flared with painful joints lasted for 2 weeks before it resolved. Additional medical history included a medication of upadacitinib indicated for moderate to severe rheumatoid arthritis and a 2-dose primary series of mRNA-1273 vaccine. Patient's joints also hurt after receiving the 2nd dose of mRNA-1273 vaccine. Further details on the medical history, clinical course, diagnostics, and treatments were not reported. Patient's age, based on the reported date of birth, and her underlying condition of rheumatoid arthritis could be considered as contributory factors to the event of condition aggravated with the symptom of painful joints. The benefit-risk relationship of mRNA-1273 is not affected by this report. Event's seriousness assessed based on medical judgement.   This case was linked to MOD-2021-620785 (Patient Link).; Sender's Comments: This spontaneous case concerns an adult, female patient with concurrent conditions of rheumatoid arthritis and chronic obstructive pulmonary disease, who experienced an unexpected, medically significant event of Condition aggravated after receiving a 3rd dose of mRNA-1273 vaccine. Exact latency of the event autoimmune flared relative to vaccination cannot be determined with unknown event's onset date and vaccine administration date. Reportedly, the event autoimmune flared with painful joints lasted for 2 weeks before it resolved. Additional medical history included a medication of upadacitinib indicated for moderate to severe rheumatoid arthritis and a 2-dose primary series of mRNA-1273 vaccine. Patient's joints also hurt after receiving the 2nd dose of mRNA-1273 vaccine. Further details on the medical history, clinical course, diagnostics, and treatments were not reported. Patient's age, based on the reported date of birth, and her underlying condition of rheumatoid arthritis could be considered as contributory factors to the event of condition aggravated with the symptom of painful joints. The benefit-risk relationship of mRNA-1273 is not affected by this report. Event's seriousness assessed based on medical judgement.